HOME > BUSINESS > Govt of India starts crack down on low-quality medicine makers

Govt of India starts crack down on low-quality medicine makers

The government of India has started conducting inspections at drug manufacturing units across the country to prevent the production of low-quality drugs and medicines in India.

Typically, inspections are conducted by state authorities, while central agencies largely confine themselves to checking quality of final products put up on store shelves.

However, in the last few years, India has seen the emergence of low quality drug makers.

These drug makers enter into deals with medicine marketing brands to supply drugs at a fraction of the price at which these are sold. Tablets that are sold for Rs 5 each, for example, can be supplied for 20 paise each by these manufacturers.

Many of these drugs have poor or zero potency or efficacy. Though these medicines do not kill or harm patients directly, they contribute to their suffering by lacking the expected efficacy or benefit and can seriously aggravate the disease.

The marketing company in turn ‘ties up’ with doctors to have their (low quality) medicines prescribed.

The doctors, in turn, prescribe the medicines of these unknown brands after being ‘persuaded’ by these agents. The profit from these operations are shared across the eco-system.

Earlier this year, Government of India’s Central Drugs Standard Control Organisation created a checklist for carrying out inspections at drug units.

Subsequently, it identified a number of companies manufacturing drugs in the country for inspections.

A team of five officers each headed by a mid level officer were thereafter deputed to carry out inspections of indentified manufacturing units for a period of three days.

These officers, drawn from CDSCO, Drug Testing Laboratories and State Regulators, were given one week training.

“So far, five rounds of such inspections involving 136 units have been carried out,” the government said.

Despite noticing deficiencies, no action could be taken against the units by the central government as manufacturing of medicines is controlled by the state governments, it added.

“Manufacture of drugs is, in terms of the Drugs & Cosmetics Act, regulated by state licensing authorities and, therefore, action against the manufacturers is required to be taken by the State Licensing Authorities,” it said.

However, said the centre, state authorities have been ‘advised’ to rectify the violations.

The center will conduct follow-up inspections next year to check whether the deficiencies have been fixed or not.

“Further inspections are planned during 2017 to cross check action taken to rectify the deficiencies noticed during inspection,” it added.

India is the world’s largest maker of non-patented medicines, and most of it is exported to markets like the US.

The US Food and Drug Administration conducts regular checks in Indian plants used to manufacture drugs sold in the country. However, checks and enforcement is generally lax in those plants that are used to make drugs for sale in India, especially by contract manufacturers.

Follow ULTRA.news
RERA sales freeze drags down DLF Q2 profit by 94%, sales restarted Real estate major DLF reported a sharp decline in its revenue and profit for the July-September quarter after it stopped taking new bookings due to the implementation of RERA in May.The company's net profit fell by 94% to Rs 12.57 cr in July-September quarter from Rs 204.60 ...
Zee Entertainment slashes channel prices ahead of TRAI regulation Zee's new tariff card for HD channelsZee Entertainment, one of the four big broadcasting groups of India, has become the first player to bring its channel prices in line with an upcoming regulation issued by the Telecom Regulatory Authority of India.Zee's new tariff card...
Net Neutrality: Vodafone wants right to manipulate Internet videos Telcos want to be able to reduce video qualityVodafone India said it would like to be given the power to manage the size of videos watched by users on its mobile network and lower it automatically "for overall quality welfare".Participating in the discussions related to ...
Complaints against telcos drop sharply as 4G takes off No of complaints against telcos in last three years. 2017 nos are annualizedComplaints against all telecom providers except Bharti Airtel dropped in 2016, possibly in reaction to the emergence of new operator Reliance Jio and the explosion of 4G data capacity.The total n...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta ta...
Reliance Jio interconnect dispute with Airtel, Idea to end this month The dispute over providing interconnection facility is set to end in the next two weeks, with Bharti Airtel, Idea Cellular and Vodafone giving in to the demands of new operator Reliance Jio and the regulator.The decision to comply comes in the wake of a recommendation for a f...
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and ...
FDA observations ‘primarily procedural’ – USFDA issued four observations about Cipla's manufacturing facilities in Goa after conducting an audit, the company said. Cipla has three facilities in Goa."The observations were primarily procedural in nature and the company has already responded to these observations," said...
Lupin receives FDA approval for generic Namenda XR dementia capsules Pharma Major Lupin Ltd said it received final approval from United States Food and Drug Administration for selling Memantine Hydrochloride extended-release capsules, a generic version of Allergan’s Namenda XR capsules.Namenda XR extended-release capsules are approved by the...
Suven Life Sciences gets two product patents in India and Japan Drug manufacturer Suven Life Sciences Ltd said it got two product patents in India and Japan for to a new compound for the treatment of disorders associated with Neurodegenerative diseases.The patents are valid through 2026-2032.The granted claims include a class of selec...
Marksans Pharma gets USFDA approval for sale of anti-allergy drug Marksans Pharma Limited, an Indian pharmaceutical company, said it has received approval from the USFDA for the sale sale of its Loratadine Liquid Filled Capsules 10 mg in the US market.Loratadine is an antihistamine that reduces the effects of natural chemical histamine in t...
Lincoln Pharma develops oral spray version of Ondansetron anti-nausea drug Lincoln Pharmaceuticals Ltd said it developed and launched an oral spray version of Ondansetron anti-nausea drug.Ondansetron is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy), radiation therapy and also in the prevention and treatment for n...
Aurobindo Pharma to launch HIV drug in Africa this year, gets tentative FDA nod Aurobindo Pharma Limited, a pharmaceutical manufacturing company based in Hyderabad, said it received a tentative approval for HIV drug Dolutegravir from US Food & Drug Administration.It is the first FDA approval of a generic version of Dolutegravir. Through a tie up w...
Sharon Bio Medicines receives FDA approval for Tajola API plant Indian Pharmaceutical company Sharon bio medicine Ltd said it received the Establishment Inspection Report (EIR) from United States Food and Drug Amnistration for its manufacturing plant located at Tajola in Raigad Dist., Maharashtra.The plant, which will make Active Pharmace...
Dr Reddy’s Laboratories launches Paricalcitol injection in the US Market Dr. Reddy's Laboratories Ltd said it launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar injection in the United States market approved by the US Food & Drug Administration (USFDA).The Zemplar brand and generic had US sales of approximatel...
Glenmark to market generic Abraxane from Lubrizol LifeSciences Glenmark Pharmaceuticals, Inc., USA said it has entered into a strategic Development, License and Commercialization Agreement with Particle Sciences, Inc. to develop and market a generic version of Celgene’s Abraxane, used for cancer treatment.As per the terms of the agreemen...
Opto Circuits subsidiary enters global market with Freeway coated shunt baloon catheter Opto Circuits, a medical technology group, said its wholly owned subsidiary, Eurocor GmbH, entered the global market with their Freeway coated shunt baloon catheter.Freeway coated shuntbaloon catheter is used for arteriovenous (AV) access to help patients with end-stage renal d...
Suven Life Sciences granted patents in Canada, Europe & Hong Kong Drug manufacturer Suven Life Sciences Ltd said it got three product patents from Canada, Europe & Hong Kong corresponding to new chemical entity for the treatment of disorders associated with Neurodegenerative diseases.The patents are valid through 2030-2032.According...
Lupin receives tentative approval for generic Rapaflo capsules Pharma Major Lupin Limited (Lupin) announced that it received tentative approval from the United States Food and Drug Administration (FDA) for selling Silodosin capsules, a generic version of Allergan Sales' Rapaflo capsules.Silodosin capsules are indicated for the treatment...
Glenmark Pharma discovers potential new anti-cancer drug Glenmark Pharmaceuticals said its overseas subsidiary has discovered a molecule that can potentially be used in targeting even difficult-to-treat lung cancer and colorectal cancer.The GBR 1372 molecule was discovered in the pharma company's Swiss laboratory and that the compa...